In The News

Canagliflozin Reduces Cardiovascular Events in Patients With Type 2 Diabetes Regardless of Cardiovascular Disease History

November 13, 2017. A prespecified data analysis from the Canagliflozin Cardiovascular Assessment Study (CANVAS) found that canagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, reduced cardiovascular (CV) events in patients with type 2 diabetes and with and without a history of CV disease (the secondary prevention cohort, n=6,656, and primary prevention cohort, n=3,486, respectively). The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

National Clinical Care Commission Act Becomes Public Law

November 2, 2017. President Trump has signed the National Clinical Care Commission Act (S. 920) to establish a public/private commission of experts and patient advocacy representatives to collectively assess federal government diabetes programs, identify inefficiencies and gaps, and provide recommendations to the US Department of Health and Human Services and Congress to improve diabetes care. Congratulations to all AACE advocates, the broad diabetes community, and industry partners who worked to support this legislation.

Insulin Degludec Is Effective in Patients With Type 1 or Type 2 Diabetes After Switching Basal Insulin

November 6, 2017. This European, multicenter, retrospective chart review (EU-TREAT) found that switching patients with type 1 or type 2 diabetes (T1D, T2D) from other basal insulins to insulin degludec improved glycemic control while significantly reducing hypoglycemia risk at 6 months. For patients with T1D and T2D, A1C decreased by a mean of −0.20% (95% confidence interval [CI]: −0.24%, −0.17%) and −0.51% (95% CI: −0.58%, −0.43%), respectively, vs baseline (all P<0.001).

Dipeptidyl Peptidase-4 Inhibitors Show Better Glycemic Durability Compared to Sulfonylureas

November 2, 2017. Eight randomized controlled trials were included in this meta-analysis that demonstrated the superior durability of glycemic response for dipeptidyl peptidase-4 (DPP-4) inhibitors vs sulfonylureas (SUs) in patients with type 2 diabetes. Changes in A1C levels were compared from an intermediate timepoint of 26 or 52 weeks’ treatment to 104 weeks.

Animas Closes Insulin Pump Business

October 28, 2017. Animas Corporation, a Johnson & Johnson Diabetes Care company, is discontinuing the manufacture and sale of insulin pumps and exiting the insulin pump market. Current users of the Animas Vibe and OneTouch Ping insulin pumps will be transferred to a Medtronic pump. Read more about the announcement here.

Improving the Utility and Value of Continuous Glucose Monitoring Systems

October 25, 2017. Continuous glucose monitoring (CGM) systems automatically track blood glucose levels over 24 hours, offering valuable information for people with diabetes. Due to challenges standardizing and understanding this technology, however, these devices remain underutilized. To help maximize the potential for CGM systems in diabetes management, a team of experts from the American Diabetes Association and the European Association for the Study of Diabetes has issued a joint scientific statement regarding the most effective and appropriate use of this technology.

FDA Approves New, Once-Weekly Extended-Release Exenatide Injection

October 23, 2017. The US Food and Drug Administration (FDA) has approved a new, extended-release formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for adults with type 2 diabetes. The new formulation, called Bydureon BCise, is delivered via a once-weekly, single-dose autoinjector device that continuously releases consistent, therapeutic levels of exenatide. In clinical trials, the drug has been shown to lower A1C levels and promote weight loss, both as monotherapy and in combination with metformin, a sulfonylurea, or a thiazolidinedione.

Semaglutide Receives Votes in Favor of Approval From the FDA

October 18, 2017. An advisory committee of the US Food and Drug Administration (FDA) voted to recommend approval of Novo Nordisk’s semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), to improve glycemic control in adults with type 2 diabetes (T2D). The decision was based on efficacy and safety data from 8 clinical trials, which involved more than 8,000 adults with T2D.

Empagliflozin Improves Urinary Albumin Excretion in Patients With Type 2 Diabetes

August 5, 2017. The effect of empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, on urinary albumin-to-creatinine ratio (UACR) was explored in an analysis of data from EMPA-REG OUTCOME, a randomized, placebo-controlled trial. In the exploratory analysis, 6,953 patients were stratified according to albuminuria status at baseline (normo-, micro-, or macroalbuminuria) and data were pooled for the empagliflozin arms (10 and 25 mg) vs placebo. UACR levels were assessed at 12 and 164 weeks.

Glycaemic Control and Hypoglycemia in Patients With Type 2 Diabetes Switching From Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL or Insulin Glargine 100 U/mL

July 24, 2017. This post-hoc analysis of 2 large, randomized controlled trials (EDITION 1 and EDITION 2) evaluated the effect of once-daily insulin glargine 300 U/mL (Gla-300) vs glargine 100 U/mL (Gla-100) over 6 months on blood glucose and hypoglycemia in patients with type 2 diabetes switching from twice-daily insulin. Change from baseline in A1C, assessed as least-squares mean difference, was similar for both groups in both studies: (EDITION 1, -0.01%; 95% confidence interval [CI]: -0.27%-0.24%; EDITION 2, 0.16%; 95% CI: -0.25%-0.57%).

Pages